pubmed-article:11861331 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11861331 | lifeskim:mentions | umls-concept:C0039005 | lld:lifeskim |
pubmed-article:11861331 | lifeskim:mentions | umls-concept:C0041951 | lld:lifeskim |
pubmed-article:11861331 | lifeskim:mentions | umls-concept:C0031133 | lld:lifeskim |
pubmed-article:11861331 | lifeskim:mentions | umls-concept:C0022616 | lld:lifeskim |
pubmed-article:11861331 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
pubmed-article:11861331 | lifeskim:mentions | umls-concept:C0205359 | lld:lifeskim |
pubmed-article:11861331 | lifeskim:mentions | umls-concept:C2348291 | lld:lifeskim |
pubmed-article:11861331 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
pubmed-article:11861331 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:11861331 | pubmed:dateCreated | 2002-3-6 | lld:pubmed |
pubmed-article:11861331 | pubmed:abstractText | 1. The influence of 5-hydroxytryptamine (5-HT) receptor agonists and antagonists on the ureter motility was investigated in vivo on intact ureters of anaesthetized pigs. Drugs were administered intravenously or topically. 2. 5-HT induced a dose-dependent increase in the frequency of ureter contractions in anaesthetized pigs when given intravenously (0.0001-1 mg kg(-1); ED(50) 0.066 mg kg(-1)) or topically (0.001-1 mg ml(-1); EC(50) 0.043 mg ml(-1)). Significant increases in heart rate and blood pressure were observed when the drug was given intravenously but not topically. 3. The 5-HT(2A) agonist, DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane) increased the frequency of ureteral contractions in a dose-dependent manner (1-300 microg kg(-1) i.v.). Calculation of ED(50) indicated this compound to be about 1.5 times more potent with an efficacy of 23% compared to 5-HT. 4. The 5-HT(2A/2C) antagonist, ketanserin (0.5 mg kg(-1)) and the 5-HT(2C) antagonist, methysergide (1 mg kg(-1)) antagonized the 5-HT-induced ureter peristalsis when given intravenously. Contraction amplitude, blood pressure and heart rate were not affected by the antagonists. 5. Intravenous (0.0001-1 mg kg(-1)) and topical (0.0001-1 microg ml(-1)) ketanserin significantly decreased the frequency of spontaneous ureteral contractions to about 30% of controls, which could be partly reversed by 5-HT (0.3 mg kg(-1) i.v.). The contraction amplitude, contractions of the contralateral, saline perfused ureter, heart rate and mean arterial blood pressure were not affected. 6. Thus, contractility of porcine ureter is mediated by 5-HT(2) receptors. Their antagonists ketanserin and methysergide seem to be promising drugs for treatment of acute ureteric colic or in preparing the ureter for ureteroscopy. | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:language | eng | lld:pubmed |
pubmed-article:11861331 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:11861331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11861331 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11861331 | pubmed:month | Feb | lld:pubmed |
pubmed-article:11861331 | pubmed:issn | 0007-1188 | lld:pubmed |
pubmed-article:11861331 | pubmed:author | pubmed-author:WeissRR | lld:pubmed |
pubmed-article:11861331 | pubmed:author | pubmed-author:ScholtysikGG | lld:pubmed |
pubmed-article:11861331 | pubmed:author | pubmed-author:StuderU EUE | lld:pubmed |
pubmed-article:11861331 | pubmed:author | pubmed-author:PortierC JCJ | lld:pubmed |
pubmed-article:11861331 | pubmed:author | pubmed-author:DanuserHH | lld:pubmed |
pubmed-article:11861331 | pubmed:author | pubmed-author:MevissenMM | lld:pubmed |
pubmed-article:11861331 | pubmed:author | pubmed-author:HauserD SDS | lld:pubmed |
pubmed-article:11861331 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11861331 | pubmed:volume | 135 | lld:pubmed |
pubmed-article:11861331 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11861331 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11861331 | pubmed:pagination | 1026-32 | lld:pubmed |
pubmed-article:11861331 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:meshHeading | pubmed-meshheading:11861331... | lld:pubmed |
pubmed-article:11861331 | pubmed:year | 2002 | lld:pubmed |
pubmed-article:11861331 | pubmed:articleTitle | Effects of ketanserin and DOI on spontaneous and 5-HT-evoked peristalsis of the pig ureter in vivo. | lld:pubmed |
pubmed-article:11861331 | pubmed:affiliation | Institute of Veterinary Pharmacology, University of Bern, 3012 Bern, Switzerland. | lld:pubmed |
pubmed-article:11861331 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:11861331 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11861331 | lld:pubmed |